Abstract
Objective
To select potential molecules that can target viral spike proteins, which may potentially interrupt the interaction between the human angiotension-converting enzyme 2 (ACE2) receptor and viral spike protein by virtual screening.
Methods
The three-dimensional (3D)-coordinate file of the receptor-binding domain (RBD)-ACE2 complex for searching a suitable docking pocket was firstly downloaded and prepared. Secondly, approximately 15,000 molecular candidates were prepared, including US Food and Drug Administration (FDA)-approved drugs from DrugBank and natural compounds from Traditional Chinese Medicine Systems Pharmacology (TCMSP), for the docking process. Then, virtual screening was performed and the binding energy in Autodock Vina was calculated. Finally, the top 20 molecules with high binding energy and their Chinese medicine (CM) herb sources were listed in this paper.
Results
It was found that digitoxin, a cardiac glycoside in DrugBank and bisindigotin in TCMSP had the highest docking scores. Interestingly, two of the CM herbs containing the natural compounds that had relatively high binding scores, Forsythiae fructus and Isatidis radix, are components of Lianhua Qingwen (莲花清瘟), a CM formula reportedly exerting activity against severe acute respiratory syndrome (SARS)-Cov-2. Moreover, raltegravir, an HIV integrase inhibitor, was found to have a relatively high binding score.
Conclusions
A class of compounds, which are from FDA-approved drugs and CM natural compounds, that had high binding energy with RBD of the viral spike protein. Our work provides potential candidates for other researchers to identify inhibitors to prevent SARS-CoV-2 infection, and highlights the importance of CM and integrative application of CM and Western medicine on treating COVID-19.
Article PDF
Similar content being viewed by others
References
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–273.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–269.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–271.
Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26:243–250.
Li XH, Hu JH, Zhang K, Ye J, Gou CY. Therapeutic effect of integrative traditional Chinese and Western medicine on 51 SARS patients and its influence on their T lymphocyte subsets. Chin J Integr Med 2003;9:263–265.
Jiao Q, Wang B, Zhang RL, Wang BG, Feng LM, Wang HJ, et al. Clinical controlled study of integrative Chinese and Western medicine in treating 49 cases of SARS. Chin J Integr Med 2003;9:175–180.
Lin L, Wang RB, Zhang YT, Tang GH. Applying integrative Chinese and Western medicine in fighting SARS. Chin J Integr Med 2003;9:162–168.
Liu BY, Hu JQ, Xie YM, Weng WL, Wang RB, Zhang YP, et al. Effects of integrative Chinese and Western medicine on arterial oxygen saturation in patients with severe acute respiratory syndrome. Chin J Integr Med 2004;10:117–122.
Wang RB, Liu JM, Jiang YY, Wu YZ, Wang XJ, Chi PP, et al. Therapeutic effects of integrated traditional Chinese medicine and Western medicine in treating severe acute respiratory syndrome. Chin J Integr Med 2003;9:259–262.
Dobos G, Tao I. The model of Western integrative medicine: the role of Chinese medicine. Chin J Integr Med 2011;17:11–20.
Li RF, Hou YL, Huang JC, Pan WQ, Ma QH, Shi YX, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020. [Epub ahead of print]
Zhang K. Is traditional Chinese medicine useful in the treatment of COVID-19? Am J Emerg Med 2020. [Epub ahead of print]
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020;155:104743.
Gao LQ, Xu J, Chen SD. In silico screening of potential Chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and angiotensin converting enzyme II using molecular docking. Chin J Integr Med 2020;26:527–532.
Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 2009;106:5871–5876.
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327–347.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:eabb2507.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444–1448.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–220.
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221–224.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–292.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074–D1082.
Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014;6:13.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–461.
DeLano WL. Pymol: an open-source molecular graphics tool. CCP4 Newsletter on protein crystallography. 2002;40:82–92.
Dassault Systèmes BIOVIA. Discovery studio modeling environment, release 2016. San Diego: Dassault Systèmes: 2016.
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894–904.
Di Pierro M, Elber R, Leimkuhler B, Computation. A stochastic algorithm for the isobaric-isothermal ensemble with Ewald summations for all long range forces. J Chem Theory 2015;11:5624–5637.
Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Exp Opin Drug Discov 2015;10:449–461.
Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2013;2:e23082.
Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012;1:4.
Jiangsu New College of Medicine. Dictionary of Traditional Chinese Drugs. Shanghai: Shanghai People’s Press; 1986.
Wei XY, Leung CY, Wong CK, Shen XL, Wong RN, Cai ZW, et al. Bisindigotin, a TCDD antagonist from the Chinese medicinal herb Isatis indigotica. J Natural Product 2005;68:427–429.
Acknowledgment
Great thanks to Dr. JIANG Kai from Department of Biology, Southern University of Science and Technology for his suggestion on our experimental design and manuscript preparation.
Author information
Authors and Affiliations
Contributions
Li HY, Wang GY and Zhang J conceived and designed the study. Wei TZ and Wang H performed the research, and contributed to this work equally as co-first authors. All the authors analyzed the data. Li HY, Wang GY, Zhang J, WEI TZ, and Wang H wrote the manuscript draft. All the authors read and approved the final version of manuscript.
Corresponding authors
Additional information
Conflicts of Interest
The authors declare no conflict of interest.
Supported by National Natural Science Foundation of China (No. 61773196), Special Scientific Research Project on COVID-19 Epidemic Prevention and Control in Guangdong Universities (No. 2020KZDZX1182), Guangdong Provincial Key Laboratory Funds (Nos. 2017B030301018, 2019B030301001), Shenzhen Research Funds (No. JCYJ20170817104740861), Shenzhen Peacock Plan (No. KQTD2016053117035204), and by Center for Computational Science and Engineering of Southern University of Science and Technology, China
Rights and permissions
About this article
Cite this article
Wei, Tz., Wang, H., Wu, Xq. et al. In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy. Chin. J. Integr. Med. 26, 663–669 (2020). https://doi.org/10.1007/s11655-020-3427-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-020-3427-6